These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17728330)

  • 41. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
    Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-TNF-alpha-induced systemic lupus syndrome.
    Debandt M; Vittecoq O; Descamps V; Le Loët X; Meyer O
    Clin Rheumatol; 2003 Feb; 22(1):56-61. PubMed ID: 12605321
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
    Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
    J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
    Ang HT; Helfgott S
    J Rheumatol; 2003 Nov; 30(11):2315-8. PubMed ID: 14677170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
    Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
    Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-tumor necrosis factor-alpha-induced psoriasis.
    Sari I; Akar S; Birlik M; Sis B; Onen F; Akkoc N
    J Rheumatol; 2006 Jul; 33(7):1411-4. PubMed ID: 16821276
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.
    Hawryluk EB; Linskey KR; Duncan LM; Nazarian RM
    J Cutan Pathol; 2012 May; 39(5):481-92. PubMed ID: 22515220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.
    Garcovich S; Burlando M; Rongioletti F; Garcovich A; Parodi A; Amerio P
    Acta Derm Venereol; 2010 May; 90(3):311-2. PubMed ID: 20526559
    [No Abstract]   [Full Text] [Related]  

  • 51. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.
    Thyagarajan V; Norman H; Alexander KA; Napalkov P; Enger C
    Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.
    Slifman NR; Gershon SK; Lee JH; Edwards ET; Braun MM
    Arthritis Rheum; 2003 Feb; 48(2):319-24. PubMed ID: 12571839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.
    den Broeder AA; Creemers MC; Fransen J; de Jong E; de Rooij DJ; Wymenga A; de Waal-Malefijt M; van den Hoogen FH
    J Rheumatol; 2007 Apr; 34(4):689-95. PubMed ID: 17117492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Adverse events during biological therapy -- focusing on dermatological side-effects].
    Nagy G; Lukács K; Sziray A; Fazekas K; Florián A; Tamási L; Károlyi Z
    Orv Hetil; 2011 Feb; 152(6):212-20. PubMed ID: 21278026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases.
    Fujikawa K; Kawakami A; Hayashi T; Iwamoto N; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Ida H; Origuchi T; Eguchi K
    Mod Rheumatol; 2010 Feb; 20(1):86-9. PubMed ID: 19812889
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
    Dinarello CA
    J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cancer in arthritis patients after anti-tumour necrosis factor therapy].
    Dreyer L; Mellemkjaer L; Hetland ML
    Ugeskr Laeger; 2009 Feb; 171(7):506-11. PubMed ID: 19210932
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.
    Liu SW; Velez NF; Lam C; Femia A; Granter SR; Townsend HB; Vleugels RA
    JAMA Dermatol; 2013 Oct; 149(10):1204-8. PubMed ID: 23986394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.